Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology–Gynecologic Oncology Group protocol 240)

The Lancet Oncology - Tập 16 - Trang 301-311 - 2015
Richard T Penson1, Helen Q Huang2, Lari B Wenzel3, Bradley J Monk4, Sharon Stockman5, Harry J Long6, Lois M Ramondetta7, Lisa M Landrum8, Ana Oaknin9, Thomas J A Reid10, Mario M Leitao11, Michael Method12, Helen Michael13, Krishnansu S Tewari3
1Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
2NRG Oncology/Gynecologic Oncology Group, Roswell Park Cancer Institute, Buffalo, NY, USA
3University of California, Irvine Medical Center, Orange, CA, USA
4University of Arizona Cancer Center and Creighton University at St Joseph's Hospital and Medical Center, Phoenix, AZ, USA
5University of Iowa Hospitals, Iowa City, IA, USA
6Mayo Clinic, Rochester, MN, USA
7MD Anderson Cancer Center, Houston, TX, USA
8Oklahoma University Health Science Center, Oklahoma City, OK, USA
9Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain
10University of Cincinnati College of Medicine/Women's Cancer Center at Kettering, Kettering, OH, USA
11Memorial Sloan-Kettering Cancer Center, New York, NY, USA
12Michiana Hematology Oncology PC-Mishawaka, Mishawaka, IN, USA
13Indiana University School of Medicine, Indianapolis, IN, USA

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

The Lancet Oncology

Tập 16

301-311

Thông tin tác giả